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Theanti-cancereffectsofmetformin,themostwidelyuseddrugfortype2diabetes,aloneorincombination
with ionizing radiation were studied with MCF-7 human breast cancer cells and FSaII mouse fibrosarcoma
cells. Clinically achievable concentrations of metformin caused significant clonogenic death in cancer cells.
Importantly, metformin was preferentially cytotoxic to cancer stem cells relative to non-cancer stem cells.
Metformin increased the radiosensitivity of cancer cells in vitro, and significantly enhanced the
radiation-inducedgrowthdelayofFSaIItumors(s.c.)inthelegsofC3Hmice.Bothmetforminandionizing
radiation activated AMPK leading to inactivation of mTOR and suppression of its downstream effectors
suchasS6K1and4EBP1,acrucialsignalingpathwayforproliferationandsurvivalofcancercells,invitroas
well as in the in vivo tumors. Conclusion: Metformin kills and radiosensitizes cancer cells and eradicates
radioresistant cancer stem cells by activating AMPK and suppressing mTOR.
M
etformin (1, 1-dimethylbiguanide hydrochloride) is the most widely used drug to treat type 2 diabetic
patients. Metformin reduces blood glucose levels by suppressing gluconeogenesis in the liver and
increasing glucose uptake by skeletal muscle
1–3. Metformin decreases blood insulin levels, increases
insulin sensitivity, suppresses synthesis of proteins, fatty acids and cholesterol, and increases free fatty acid
utilization
1–3. In addition, metformin has been shown in the last several years to possess strong anti-cancer
effects
3–7. Use of the drug by type 2 diabetic patients significantly suppressed development of cancers in breast
8,
pancreas
9,and lung
10,while diminishing cancer-related mortality. Furthermore, the response of diabetic patients
withbreastcancertoneoadjuvantchemotherapywasmarkedlybetterinthosetreatedwithmetforminratherthan
other anti-diabetic drugs
11. In a number of recent preclinical studies, metformin reduced proliferation of cancer
cells and induced apoptotic and clonogenic death of cancer cells in vitro
4,12–15, caused cell cycle arrest
13,15 and
reduced incidence and growth of experimental tumors in vivo
16,17. These impressive epidemiological and pre-
clinical results led to the recent commencement of several clinical trials evaluating the anti-cancer properties of
metformin in combination with conventional chemotherapeutic drugs
3–6.
The PTEN/PI3K/Akt/mTOR signaling pathway plays a central role in survival and proliferation of cancer
cells
18–23. This pathway is frequently mutated in cancer cells, leading to dysregulation of cell proliferation,
differentiation, and survival. Metformin disrupts mitochondrial respiration leading to an imbalance of the
AMP:ATP ratio. Increase in the level of AMP relative to ATP activates 5’ AMP-activated protein kinase
(AMPK), which then suppresses the activity of mTOR
12–17,24. Therefore, suppression of mTOR through
AMPK activation is believed to constitute the major mechanism underlying the anti-cancer activities of metfor-
min
12–17,21,22. Metformin has also been reported to directly inactivate mTOR in certain cell lines
3. It has been
reported recently that ionizing radiation activates AMPK
25–27, and that metformin enhances the radiation-
induced AMPK activation and cancer cell death
25. Metformin has also been demonstrated to amplify chemo-
therapy-induced AMPK activation
24.
Recentevidenceunequivocallyindicatesthatasmallproportionofcellsinhumancancersarecancerstemcells
(CSCs) (also termed tumor-initiating cells)
28–31, and CSCs are both chemoresistant
31–35 and radioresistant
35–38
compared with non-cancer stem cells (non-CSCs). Importantly, it has been reported that metformin markedly
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chemotherapy drugs by eradicating CSCs in the tumors
39–41.
In the present report, we show that metformin is potentially effec-
tive to enhance the response of cancers to radiotherapy by killing
cancer cells preferentially CSCs, and by radiosensitizing cancer cells.
Our preliminary results have previously been reported
42,43.
Results
Metformin is cytotoxic to cancer cells. Metformin reduced the
clonogenic survival of FSaII mouse fibrosarcoma cells and MCF-7
human breast cancer cells in dose and time-dependent manner as
shown in Fig. 1. In FSaII cells (Fig. 1A), incubation with 1.0 mM
metformin for 1 h reduced the clonogenic survival of cells to 65.1%,
and incubation for 24 h or 48 h reduced the survival to 49.3% and
28.7%, respectively. Incubation of MCF-7 cells with 1.0 mM met-
formin for 24 or 48 h decreased the cell survival to 81.7% and
71.0%, respectively (Fig. 1B). We investigated the effects of a long-
term exposure of cells to clinically relevant concentrations of met-
formin (6–30 mM)
15,22. on the survival of cancer cells. Figure 1C
shows that culturing FSaII cell in media containing 5 mMm e t -
formin reduced the clonogenic survival to 66.4%, and culturing
FSaII and MCF-7 cells with 30 mM metformin decreased the
survival to 64.1% and 71.9% respectively. When cells were cultured
in the presence of metformin in the above mentioned studies, the size
of resultant colonies and the cell density in the colonies werefound to
bereduced ascompared with the colonies formed inregular medium.
Itwasthusclearthatmetforminnotonlykilledcancercellssothatthe
number of colonies formed were reduced, but it also suppressed the
proliferation of surviving cells. We also studied whether metformin
causes apoptotic death by flow cytometric determination of sub-G1
cells, annexing V staining and Western blot analysis of PARP and
caspase-3 cleavage. The incubation for 48 h with 1–5 mM metfor-
min caused little apoptosis in both MCF-7 and FSaII cells (see Sup-
plementary Fig. S1 online). It thus appeared that apoptotic death did
not contribute significantly to the total cell death, i.e. clonogenic cell
death, caused by metformin in the present study.
Metformin sensitizes cancer cells to radiation. The radiation
survival curves of FSaII and MCF-7 cells treated with metformin
for 24 h before and 24 h after irradiation were steeper than the
radiation survival curves of control cells (Figs. 1D and E). The
radiosensitization caused by metformin was statistically significant
at radiation doses higher than 3 Gy (P,0.05).
Metformin and irradiation activate AMPK and suppress mTOR,
S6K1 and 4EBP1. Figure 2A shows that, in MCF-7 cells incubated
with 5 mM metformin, the levels of p-AMPK gradually increased
becoming significant after incubation for 16 h whereas the levels
of p-mTOR and its downstream targets p-S6K1 and p-4EBP1
decreased after incubation with 5 mM metformin for 24 h. The
levels of p-ACC, a substrate of p-AMPK, also increased as a result
of activation of AMPK. These changes in the signals were further
amplified when the incubation with 5 mM metformin was pro-
longed to 48 h. Irradiation of MCF-7 cells with 4 Gy gradually
increased p-AMPK levels and slightly decreased the levels of p-
mTOR, p-S6K1 and p-4EBP1 from 16 h post-irradiation. The
levels of p-AMPK, p-mTOR, p-S6K1 and p-4EBP1 at 48 h after
irradiation were almost similar to those at 16 h post-irradiation
(Fig. 2A). As shown in Fig. 2B, the treatment of MCF-7 cells
for 48 h with 1 or 5 mM metformin in combination with 4 Gy
irradiation was far more effective than metformin or irradiation
alone to increase p-AMPK and p-ACC and to decrease p-mTOR,
p-S6K1, and p-4EBP1. Similar results were observed with FSaII cells
(Fig. 2C): incubation with 1 mM metformin for 24–48 h increased
p-AMPK and p-ACC levels and decreased p-mTOR, p-S6K1 and p-
4EBP1 levels, and the combination of metformin with irradiation
were far more effective than metformin or irradiation alone in
activating AMPK and decreasing the phosphorylation of mTOR,
S6K1 and 4EBP1. Detailed analysis on the changes in p-AMPK
and p-mTOR in MCF-7 cells caused by metformin alone, radiation
alone and combined are shown in Supplementary Fig. S2 online.
Inhibition of AMPK reduces the cytotoxic and radiosensitizing
effect of metformin. Transfection of MCF-7 and FSaII cells with
siRNA for AMPK markedly suppressed the AMPK level (Fig. 3A).
The metformin-induced cell death (Fig. 3B) and the metformin-
induced radiosensitization (Fig. 3C) were also significantly reduced
by the transfection of the cells with AMPK siRNA.
Metformin is preferentially toxic to CSCs or CS-like cells relative
tonon-CSCs.ItiswellestablishedthatCSCsofhumanbreastcancer
cells such as MCF-7 cells are characterized with CD44
high/CD24
low
surfacemarkers
28,31,37,39–41,44.Inarepresentativeexperiment(Fig.4A),
2.78% of MCF-7 cells were CD44
high/CD24
low cells, i.e. CSCs, and a
48 htreatmentwith1 mMor5 mMmetforminreducedthefraction
of CD44
high/CD24
low cells to 2.20% and 1.29%, respectively. The
results of 7 experiments are summarized in Fig. 4B. The fraction of
CD44
high/CD24
lowcellsbeforetreatmentwas3.4%andthefractionof
CD44
high/CD24
low cells in the surviving cells after 48 h metformin
treatment decreased in dose-dependent manner. For example, the
fraction of CD44
high/CD24
low cells in the cell population which
Figure 1 | Clonogenic death of FSaII and MCF-7 cells treated with
metforminaloneorwithradiation. (A,B)Cellswereincubatedfor1–48 h
with 0.5–10 mM metformin and the clonogenic survival was determined.
(C) Cells were cultured in media containing 5–100 mM of metformin for
10 days for FSaII cells and 20 days for MCF-7 days. (D, E) Cells were
incubated with 1 or 5 mM metformin for 24 h, irradiated with various
doses of X-rays, further incubated with metformin for 24 h and then the
clonogenic survival was determined. The radiation survival curves were
normalized for the cell death caused by metformin alone. All data points
are means of 5–7 independent experiments 6 1 S.E.
www.nature.com/scientificreports
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(P,0.05).
It has been shown that CSCs in various cancers express high-level
of aldehyde dehydrogenase (ALDH1) activity, and thus ALDH1-
positive CSCs can be isolated by flow cytometry
44–46. Representa-
tive results of the effect of metformin on the proportion of
ALDH1-positive cells, putative CSCs or CS-like cells, in the FSaII
cells are shown in Fig. 4C. The proportion of ALDH1-positive FSaII
cells was initially 2.72%, and it decreased to 1.66 and 0.80% after an
48 h incubation with 0.1 and 1 mM metformin, respectively. The
means of 5–7 determinations are shown in Fig. 4D. Before the treat-
ment, 1.92% of FSaII cells were ALDH1-positive, and incub-
ation with 0.1 mM metformin for 48 h reduced the proportions of
ALDH1-positive cells in the surviving cells to 1.08% (P,0.05).
The activities of ATP-binding cassette (ABC) transporters includ-
ing the ABCG2 transporter are markedly elevated in CSCs
32.
Therefore, when cells are incubated with certain dyes such as the
fluorescent Hoechst 33342, CSCs expel the dye whereas non-CSCs
do not, thus making it possible to identify CSCs as side population
(SP) cells by flow cytometry
44,47. Representative data on the metfor-
min-induced changes in the fraction of SP cells (putative CSCs) of
FSaIIcellsareshowninFig.4E:proportionofSPcellsdecreasedfrom
2.15% in the control to 0.88% after a 48 h incubation with 5 mM
metformin. Given that CD44
high/CD24
low cells are CSCs of breast
cancer
28,31,37,39-41,44, and ALDH1-positive cells are putative CSCs or
CS-likecells
44–46andSPcellsarealsoputativeCSCsofmanydifferent
cancer cell lines
44,47, the decreases in the proportion of CD44
high/
CD24
low cells, ALDH1-positive cells and SP cells by metformin
clearly indicated that metformin is preferentially cytotoxic to CSCs
or CS-like cells relative to non-CSCs in MCF-7 and FSaII cells, as
observed in other cell lines
39–41, We have observed similar results in
humanMIAPaCa-2pancreaticcancercellsandhumanA549human
cancer cells
42,43.
Metformin impedes sphere formation. CSCs grow as spheres
(tumor-spheres) upon incubation in non-adherent conditions
39,40,44.
When 1,000 MCF-7 cells were incubated for 8 days in metformin-
free sphere medium, 44 6 3 spheres with . 50 mM diameter were
formed while 32 6 2 and 13 6 2 spheres were formed when
incubated with 0.1 mM or 0.5 mM metformin, respectively. The
numbers of FSaII spheres also declined when cultured with
metformin. In addition to the decline in the number of sphere
formed, the size of spheres formed upon incubation with 0.1 mM
metformin was clearly smaller than those in the medium without
metformin (Fig. 5A).
CSCs or CS-like cells are radioresistant. Figure 6A shows that, in a
representative study, 3.14% of MCF-7 cells were CD44
high/CD24
low
cells, i.e. CSCs, and irradiation with 3 or 5 Gy followed by a 48 h
incubation increased the fraction of CD44
high/CD24
low cells to 4.82%
and 6.05%, respectively. Such an increase in the fraction of CD44
high/
CD24
low cells after irradiation indicated that CSCs are more
radioresistant than non-CSCs. Importantly, maintaining MCF-7
cells with 1 mM metformin for 48 h after irradiation reduced the
radiation-induced increase in the fraction of CSCs. The means of 5
experiments (Fig. 6B) showed that 1 mM metformin significantly
suppressed the increase in the CSCs fraction caused by 3–7 Gy
irradiation in MCF-7 cells. As shown in Fig. 5C, irradiation with 3
or5GysignificantlyincreasedthefractionsofALDH1-positiveFSaII
cells, and metformin attenuated the radiation-induced increase in
the fraction of ALDH1-positive cells.
Metformin enhances the efficacy of radiation to suppress tumor
growth. Figure 7A shows that the treatment of C3H mice bearing
FSaIItumorsinthehindlegs(s.c.)withmetforminat25 mg/kgtwice
a day (i.p.) slightly reduce the tumor growth. On the other hand,
irradiation of tumors with 20 Gy markedly suppressed the tumor
growthstartingabout12dayspost-irradiation.Whenhostmicewere
treated with 25 mg metformin/kg twice a day, and tumors were
irradiated 1 h after the first metformin treatment, tumor growth
was markedly suppressed. Consequently, the days required for
4-fold increase in tumor volume were 17 6 3 days after 20 Gy
irradiation whereas it was 28 6 4 days after the combined
treatment with irradiation and metformin. The difference i.e. 17
v.s. 28 days, was statistically significant (P,0.001). The appearance
ofskinoverthetumorstreatedwithradiationaloneandthosetreated
with metformin in combination with radiation were similar.
TorevealwhetherAMPK/mTORsignalingpathwayplaysanyrole
in the response of tumors to metformin and irradiation, we investi-
gated the expression of p-AMPK and p-mTOR in the tumors using
immunohistological method (Figs. 7B–E). In the FSaII tumors
Figure 2 | Westernblottingfortheeffectofmetformin,4 GyirradiationorcombinedonthesignalsassociatedwithAMPK/mTORpathwayinMCF-7
and FSaII cells. Whole cell lysates were prepared and Western blot analysis was conducted using anti-p-AMPK, -AMPK, -p-ACC, -ACC, -p-mTOR,
-mTOR,-p-S6K1,-S6K1,-p-4EBP1and-4EBP1antibodies.Experimentswererepeated4-5timesandtherepresentativeresultsareshown.Thenumbers
under each blot are intensity of the blot relative to that of untreated control.
www.nature.com/scientificreports
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p-AMPK significantly increased. The level of p-AMPK also signifi-
cantly increased 6 days after 20 Gy irradiation. When tumors were
irradiated 1 h after the first metformin treatment, the increase in p-
AMPK expression was more pronounced than that occurred by
metformin or irradiation alone (Figs. 7B and C). In contrast to the
increaseinp-AMPKlevels,p-mTORlevelswasmarkedlysuppressed
by metformin and irradiation alone or combined (Figs. 7D and E).
Similar results were obtained with MCF-7 tumors grown in nude
mice (see Supplementary Fig. S3 online).
Discussion
This study has shown that metformin is cytotoxic to cancer cells at
clinically achievable concentrations. Importantly metformin was pref-
erentially cytotoxic to CSCs or CS-like cells relative to non-CSCs.
Furthermore metformin increased the radiosensitivity of cancer cells
in vitro and it markedly enhanced the response of experimental
tumors to irradiation suggesting that the anti-diabetic drug metformin
is potentially useful to enhance the efficacy of radiotherapy of cancer.
Activation of AMPK and suppression of mTOR appeared to play an
important role for the cytotoxic and radiosensitizing effect of metfor-
min in vitro as well as in vivo.
Treatment of FSaII and MCF-7 cells with metformin at concen-
trations as low as 0.5 mM for 1–48 h significantly reduced clono-
genic survival of the cells (Fig. 1). The plasma concentrations of
metformin of type 2 diabetic patients treated with metformin are
elevated to 6–30 mM range
15,22. As shown in Fig. 1C, the long-term
incubation of MCF-7 or FSaII cells with media containing 5–30 mM
metformin reduced the clonogenic survival of cells by about 30%
(Fig. 1C). In addition to inducing clonogenic death, the prolonged
exposure to 5–100 mM of metformin markedly reduced the size of
colonies formed and decreased the cell density in the colonies (data
notshown)indicatingthatmetforminnotonlykillscancercellsbutit
also suppresses the proliferation of surviving cancer cells, in agree-
ment with the reports by other investigators
14,21. The mode of cell
death caused by metformin is unknown, but our studies indicated
that apoptotic death contribute little to the total clonogenic cell
death. It appeared that cells undergo necrotic death rather than
apoptosis upon treatment with metformin (see Supplementary Fig.
S1 online). Another potentially important feature of metformin was
Figure 3 | Effects of AMPK siRNA on the cytotoxic and radiosensitizing effects of metformin. (A) Transfection of MCF-7 and FSaII ells with siRNA
against AMPK markedly reduced the AMPK levels in the cells. (B) Transfection of cells with AMPK siRNA markedly reduced the clonogenic cell death
caused by 48 h incubation with various concentrations of metformin. (C) Transfection of cells with AMPK siRNA reduced the efficacy of metformin to
sensitize the cells to radiation. Cells were incubated with 1 or 5 mM metformin for 24 h, irradiated with various doses of X-rays, further incubated with
metforminfor24 handthenculturedforcolonyformation.Theradiationsurvivalcurveswerenormalizedforthecelldeathcausedbymetformin alone.
www.nature.com/scientificreports
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significantly increased their radiosensitivity (Fig. 1D).
Increasing evidence indicates that the P13K/Akt/mTOR pathway
plays crucial role in the survival and proliferation of cancer cells
3–
5,18–20. Metformin has been shown to inactivate mTOR via activation
ofAMPK,thereby causing cellcyclearrest,apoptosis,and clonogenic
death, and inhibition of tumorigenesis
3,5,12–17,21. In the present study,
in excellent agreement with the previous reports, metformin mark-
edly activated AMPK and inactivated mTOR, thereby decreasing the
levels of downstream effectors p-S6K1 and p-4EBP1 in MCF-7 and
FSaII cells in vitro (Fig. 2). Importantly, as reported by others
25–27,
irradiationalsoactivated AMPKleading to reduction of p-mTOR, p-
S6K1 and p-4EBP1 in the present study (Fig. 2). Combination of
metformin and irradiation was more efficient than either radiation
or metformin alone to activate AMPK and inactivate mTOR and its
targets S6K1 and 4EBP1 (Figs. 2B and C). Similar to our observation,
metformin markedly enhanced the radiation-induced activation of
AMPK in cancer cells
25. However, other investigators reported that
ionizing radiation caused mTOR activation rather than mTOR inac-
tivation in various cell lines
27,48,49 particularly in the absence of
AMPK activity
27. In these studies, mTOR activation was observed
in 1–6 h after irradiation, while in our study, inactivation of mTOR
occurred from 16 h after irradiation. In a recent study, mTOR was
activated for 6 h after irradiation and then inactivated thereafter
50.
Such an increase in mTOR activity after irradiation may be attrib-
uted toradiation-induced activationof Akt
26. We may then speculate
that mTOR activity is transitorily increased after irradiation, but the
increase is eventually subdued as a result of progressive increase in
Figure 4 | EffectofmetforminontheCSCsorCS-likecells. Cellswereincubatedwithdifferentconcentrationsofmetforminfor48 h,dispersedtosingle
cells, washed, and the fraction of CSCs or CS-like cells were analyzed. (A) FACS for CD44
high/CD24
low cells of MCF-7 cells treated with 0.5–5.0 mM
metformin for 48 h. (B) % of CD44
high/CD24
low MCF-7 cells in the surviving cells after treating with different concentrations of metformin for 48 h.
Meansof7experiments61S.Eareshown.Thedeclinesin%ofCD44
high/CD24
lowcellsby0.5–10 mMmetforminwerestatisticallysignificant(P,0.05).
(C) FACS for ALDH1-positive FSaII cells treated with metformin for 48 h. (D) % of ALDH1-positive cells of FSaII cells treated with different
concentrations of metformin for 48 h. Means of 5–7 experiments 6 1 S.E are shown. The declines in % of ALDH1-positive cells by 0.1–1.0 mM
metforminwerestatisticallysignificant(P,0.05).(E)Changesin%ofSPcellsinFSaIIcellstreatedwithdifferentconcentrationsofmetforminfor48 h.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 362 | DOI: 10.1038/srep00362 5AMPK activity. These observations are of interest since inhibition of
mTOR activity with rapamycin or RAD100 markedly increased the
cellular radiosensitivity
48,49. As shown in Fig. 3, inhibition of AMPK
activity with AMPK siRNA significantly reduced the cytotoxic and
radiosensitizing effects of metformin against MCF-7 and FSaII cells,
in agreement with the report by others
24. Together, it may be reas-
onable to conclude that the metformin-induced cell death and radio-
sensitization of cancer cells (Fig. 1) are caused by the metformin-
induced activation of AMPK and resultant inactivation of mTOR.
The significant decline in the fraction of CD44
high/CD24
low cells,
i.e. CSCs, of MCF-7 cells and ALDH1-positive cells and SP cells of
FSaII (Fig. 3) by metformin indicated that metformin is preferen-
tially cytotoxic to CSCs or CS-like cells compared with non-CSCs.
Our results are in excellent agreement with the recent observations
by others that metformin selectively killed CSCs in various cell
lines
39–41. We have previously observed similar results in other
human cancer cell lines including MIAPaCa-2 pancreatic cancer
and A549 lung cancer cells
42,43. CSCs have been known to grow as
spheres (tumor-spheres) when incubated in non-adherent condi-
tions
39,40,44. Metformin at concentrations as low as 0.01 mM could
suppress the number and size of spheres derived from both MCF-7
cells and FSaII cells (Fig. 5) further supporting the conclusion that
CSCs or CS-like cells are more vulnerable to metformin than non-
CSCs. As pointed out above, inactivation of mTOR may be a major
mechanism for the anti-cancer effects of metformin. The PI3K/Akt/
mTOR pathway has been reported to be activated in more aberrant
manner in CSCsthan non-CSCs
18–20,29,30so that CSCs are more sens-
itivethannon-CSCstosuppressionofmTOR.Indeed,suppressionof
Akt or mTOR was preferentially toxic to CSCs relative to non-
CSCs
19,22,23.Therefore,wemayconcludethatthemetformin-induced
suppression of mTOR via AMPK activation is more toxic to CSCs or
CS-like cells than non-CSCs.
Incontrasttotheeffectofmetformin,ionizingradiationincreased
the relative proportion of CSCs or CSC-like cells (Fig. 6) indicating
that CSCs or CS-like are radioresistant as compared with non-CSCs.
Other investigators also reported that CSCs were radioresistant
35–38
although the mechanism for the radioresistance of CSCs has not yet
been clearly defined. Importantly, metformin significantly reduced
theradiation-inducedincreaseinthefractionofCSCsorCS-likecells
(Fig. 6), which may be attributed to metformin-induced death of
CSCs or CS-like cells. It is also possible that metformin sensitized
CSCs or CS-like cells to radiation. Further studies are needed to
reveal this intriguing and potentially important question.
Treatment of mice bearing FSaII tumors (s.c.) in the legs with
metformin at 50 mg/kg/day (i.p.) slightly suppressed the growth of
tumors (Fig. 7), in agreement with the reports by others
33,51,52.
Although the inhibition of tumor growth by metformin alone was
small in the present study (Fig. 7), the drug markedly enhanced the
response of tumors to irradiation. Such a marked suppression of
tumor growth by the combined treatment may be attributed, at least
in part, to the pronounced suppression of mTOR activity as a result
ofAMPKactivation inthe tumor cells (Fig. 7). Based on the resultsof
in vitro studies, we may further speculate that metformin caused
death of cancer cells, suppressed the proliferation of cancer cells,
radiosensitized cancer cells, and eradicated or radiosensitized CSCs.
Further studies are warranted to reveal the exact mechanisms by
which metformin causes the remarkable increase in the radiore-
sponse of tumors. The maximum safe dose of metformin for human
is 2,550 mg/day for average size person of 60 kg
53. In the present
study, the dose of metformin given to mouse was 50 mg/kg/day,
which is equivalent to 240 mg/day for 60 kg person according to a
formula suggested by the National Institute of Health (U.S.A.)
53.
Therefore, the dose used for mouse in the present study was only
about one-tenth that for the recommended safe dose for human.
It would be of interest to determine the proportion of CSCs in the
tumors before and after treatment. The present study on the com-
bined effect of metformin and a large single dose of radiation against
tumor is relevant to the current trend of hypofractionated radio-
therapy with high-dose per fraction using stereotactic techniques.
However,theefficacyofmetformintoenhancetheresponseoftumors
to conventional fractionated radiotherapy remains to be determined.
Nevertheless, our results clearly indicated for the first time that met-
formin is potentially effective to enhance the efficacy of radiotherapy.
Methods
Cell lines. FSaII fibrosarcoma cells of C3H mice and MCF-7 human mammary
adenocarcinoma cells obtained from the American Type Culture Collection
(Manassas, VA) were used. We have previously used FSaII cells for various
radiobiological research
54.
Clonogenic survival of cancer cells. Cells in exponential growth phase were treated
with metformin at 37uC for various lengths of time. Cells were then washed twice,
culturedin drug-freeregularmedium(10–12 days for FSaIIcells and 20 daysforMCF-
7 cells), colonies formed were fixed and stained
51. The numbers of colonies containing
more than 50 cells were counted and the surviving fractions wee calculated.
Effect of metformin on the radiation-induced death of cancer cells. Cells were
incubated with metfomin for 24 h before and 24 h after irradiation, and their
clonogenic survival was determined. Cells treated with metformin for 48 h without
exposure to radiation or those exposed to irradiation only were used as controls.
Irradiationofcellswereperformedwith250 kVorthovoltageX-rays(PhilipsMedical
System).
EffectofAMPKsiRNAonthecytotoxicandradiosensitizingeffectsofmetformin.
Cells were transfected with AMPK siRNA and then investigated the response of cells
to metformin and irradiation alone or combined. siRNA duplexes targeting human
AMPK was purchased from Dharmacon (Lafayette, CO). siRNA duplexes targeting
mouse AMPK was purchased from Santa Cruz. AccuTarget
TM negative control
siRNA (Invitrogen, Carlsbad, CA) was used as a negative control. LipofectAMINE
2000 (Invitrogen) was used to transfect siRNA duplexes at final concentrations of
50 nM according to the manufacturer’s recommendations.
Analysis of signaling pathway by Western blot. Cells were lysed, proteins were
separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to
Figure 5 | Effect of metformin on the growth of spheres of MCF-7 and
FSaIIcells. Cellswereculturedfor8daysinultralowattachmentwellswith
spheremediacontainingdifferentconcentrationsofmetformin.(A)MCF-
7 spheres grown with or without 0.1 mM metformin. (B) The numbers of
sphere with . 50 mm in diameter obtained from 10
3 cells. Means of 5
experiments61S.Eareshown.*P,0.05betweencontrolandmetformin
treated groups.
www.nature.com/scientificreports
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milk in Tris-buffered saline with 0.05% Tween20 and incubated with antibodies
against proteins of interest(Antibodies against p-AMPK (Thr172), p-ACC (Ser79),
p-mTOR (Ser2448), p-S6K1 (Thr389), p-4EBP1(Thr37/46), AMPK, ACC, mTOR,
S6K1, 4EBP1 and b-actin were obtained from Cell Signaling Technology (Beverly,
MA))
51. The blots were labeled with goat anti-rabbit or anti-mouse IgG conjugated
with horseradish peroxidase, and visualized with chemiluminescence (SUPEX,
NeuroNex, Korea). The band intensities were measured using ImageJ 1.41 software
(NIH, Bethesda, MD).
Effect of metformin on CSCs or CS-like cells. MCF-7 cells. MCF-7 cells were in-
cubated with metformin for 24 or 48 h, enzymatically dispersed into single cells,
washed, and suspended in PBS. Cells were next incubated for 20 min with anti-CD44
antibody (FITC-conjugated 555478, BD Biosciences, Franklin Lakes, N.J.) followed by
incubation with phycoerythrine-conjugated anti-CD24 antibody (BioLegend, San
Diego, CA) for 20 min in the dark at 4uC, washed with PBS containing 1% (v/v) FCS,
and then CD44
high/CD24
low cells were identified using flow cytometry
37,39,40. FSaII cells.
The CSCs or CS-like cells of FSaII cells were identified using the Aldefluor assay
method and also the Side population assay method
44–46. Aldefluor assay
44–46: FSaII cells
were treated with metformin for 24 or 48 h and washed. The cells were then dispersed
into single cells, and the ALDH activity was determined following the manufacturer’s
instruction (BODIPY-aminoacetaldehyde, Stemcell Technology, Vancouver, Canada).
Side population assay: FSaII cells were treated with metformin for 24 or 48 h and
washed. The cells were then dispersed into single cells, incubated with Hoechst 33342
(Sigma, St Louis, MO) at 50 mmol/mL either alone or in combination with the ABC
transporter inhibitors verapamil (50 mmol/mL) (Sigma, St Louis, MO) and FTC
(10 mM) for 90 min at 37uC. After washing, SP cells were identified using flow
cytometry
44,46.
Effectofmetformin onsphereformation. FSaIIand MCF-7cells wereplatedinsix-
wellultralowattachmentplates(Corning,Lowell,MA)atadensityof1000 cells/plate
in serum-free RPMI medium supplemented with 20 ng/mL BGF, 20 ng/mL EGF,
5 mg/mL bovine insulin and 2% (v/v) B27, and containing no or various
concentrations of metformin. After incubation for 8 days, the numbers of spheres
with diameter . 50 mM were counted under a microscope
39,40,44.
RadiosensitivityofCSCsorCS-likecells.MCF-7cellsorFSaIIcellsinexponentially
growth phase were irradiated and incubated with or without 1 mM metformin for
48 h. The fraction of CD44
high/CD24
low cells in MCF-7 cells and that of ALDH1-
positive cells or side population cells in FSaII cells were assessed using the methods
described above.
Figure 6 | Effects of metformin on the radiosensitivity of CSCs or CS-like cells. (A) MCF-7 cells were irradiated, incubated with or without 1 mM
metformin for 48 h and analyzed for CD44
high/CD24
low cells. (B) % of CD44
high/CD24
low MCF-7 cells after irradiation and 48 h incubation with 1 mM
metformin.Meansof5experiments61S.E.*P,0.05forIR-inducedincreases.**P,0.05betweenIRandIR1Metformin.(C)%ofALDH1-positive
FSaII cells after irradiation and 48 h incubation with 1 mM metformin. Means of 5 experiment 6 1 S.E. *P , 0.05 for IR-induced increases. **P , 0.05
between IR and IR 1 1 mM Metformin groups.
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5 FSaII cells in 0.05 mL of serum-free medium were
subcutaneously injected into right hind legs of 7–8 weeks-old male C3H mice. When
tumors grew to about 150 mm
3 in volume, mice were randomly divided into the
following four groups: (a) control, (b) metformin, (c) irradiation, (d) metformin plus
irradiation. The groups (b) and (d) animals were treated twice a day with metformin
by i.p. injection of 25 mg/kg drug dissolved in 0.1 mL saline (50 mg/kg/day). The
irradiationonlygroup(groupc)receivedi.pinjectionof0.1 mLsalinetwiceaday.For
theirradiationoftumors(groupcandd),micewereanesthetized byi.p.injectionofa
mixture of 100 mg/kg ketamine and 10 mg/kg xylazine, the body was covered with a
2 mm thick lead sheet, and tumor-bearing legs were locally exposed to 20 Gy of
radiation in a single dose with 250 kV orthovoltage X-ray machine (Philips Medical
System). Tumor diameter was measured using a caliper, and tumor volume was
calculated
53. At the end of the study, mice were euthanized by CO2 asphyxiation. All
the animal experiments were performed following a protocol approved by the
University of Minnesota Institutional Animal Care and Use Committee (Protocol
number 0112A13064).
Immnunohistochemistry. Tumors treated with metformin and radiation alone or
combined were excised, snap frozen in liquid nitrogen and subsequently cut in 5 mm
sections.Preparationandproceduresforthefrozentumorsectionswereperformedas
described earlier with some slight modifications
55-57. Briefly, sections were incubated
for 30 min with PBS/5% BSA/3% FBS, and subsequently incubated with either p-
AMPK, or p-mTOR antibody (Cell Signaling). After one hour incubation the slides
werewashedthoroughlywithPBS/5%BSA/3%FBSandthesecondaryantibodyanti-
rabbit IgG fluorescein iso-thiocyanate (FITC) was added (Sigma, St Louis, MO)
56.
One hour later, after a thorough wash, images of the sections were acquired on an
OlympusIX70InvertedMicroscopeat200xmagnificationanddigitallyanalyzedand
differentially quantified by morphometric analysis
57.
Statistics. The means of each group were compared with one-tail student’s t-test.
P , 0.05 was considered significant.
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